The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1292
August 11, 2008
View Complete Issue         Table of Contents 2019 
Methylnaltrexone (Relistor) for Opioid-Induced Constipation
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Methylnaltrexone (Relistor) for Opioid-Induced Constipation
August 11, 2008 (Issue: 1292)
The FDA has approved subcutaneous injection of methylnaltrexone (Relistor - Wyeth/Progenics), a selective mu-opioid receptor antagonist, for treatment of opioid-induced constipation in patients with advanced illness (such as incurable cancer or...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Methylnaltrexone (Relistor) for Opioid-Induced Constipation
Article code: 1292b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.